心脏神经移除:一种新的治疗方法用于血管失眠
Andrea Saglietto1,2,3, Giulio Falasconi3,4, Diego Penela3,5
1Division of Cardiology, Cardiovascular and Thoracic Department, "Citta della Salute e della Scienza" Hospital.
Journal of cardiovascular medicine (Hagerstown, Md.)
|February 20, 2025
概括
心脏神经衰变 (CNA) 为血管反射失联提供了一种新的治疗方法. 本综述涵盖了患者选择,程序和中期结果,突出了需要标准化和进一步研究的领域.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 神经学 神经学
背景情况:
- 血管反射失眠 (VVS) 显著影响生活质量.
- 目前对VVS的管理策略存在局限性.
- 心脏神经衰变 (CNA) 是一种新兴的治疗选择,用于耐火性VVS.
研究的目的:
- 审查目前关于心脏神经衰竭 (CNA) 血管反射失联的证据.
- 批判性地评估患者选择,程序技术和CNA的中期结果.
- 确定CNA对VVS管理的挑战和知识差距.
主要方法:
- 对最近关于心脏神经衰竭的研究进行系统审查.
- 对程序成功率和并发症的批判性评估.
- 对患者选择标准和随访数据的分析.
主要成果:
- 心脏神经衰变显示为治疗血管反射失眠的有前途.
- 中期效应令人鼓舞,但程序标准化缺乏.
- 持续面临的挑战包括协调数据收集和理解长期影响.
结论:
- 心血管神经移除是选择患有血管反射失眠的患者的可行选择.
- 需要进一步的研究来建立标准化的方案,并评估长期的安全性和有效性.
- 研究对心室失常敏感性和运动能力的影响至关重要.
相关概念视频
Disturbances in Heart Rhythm
870
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
870
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
703
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
703
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371
Mechanism of Cardiac Arrhythmias
879
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
879
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
441
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
441


